Anti Cancer Tablet And Injection

Approx. Rs 25,333 / VialGet Latest Price

Product Details:

Xgeva Solution for Injection is a medicine used in the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. It makes the bones strong and reduce the risk of fractures.

Xgeva Solution for Injection is given by a healthcare professional and should not be self-administered. You should use it regularly and at the same time each day to get maximum benefit from it. Continue using it as recommended by your doctor and complete the dose even if you feel better. To make it more effective, take adequate amount of calcium and vitamin D supplements while on treatment with this medicine.

Some common side effects of this medicine include pain in extremity, musculoskeletal pain, nerve pain, urinary tract infection, constipation, and rash. Talk to your doctor if any of these side effects does not go away with time or get worse. Your doctor may help with ways to reduce or prevent these symptoms.

To make sure the medicine is safe for you, before taking it, let your doctor know of all the other medicines you are taking. It is important for pregnant and breastfeeding mothers to ask the advice of their doctors before using this medicine.

Approx. Rs 40,000 / BoxGet Latest Price

Product Details:

INDICATIONS AND USAGE EXKIVITY is indicated for the treatment of adult patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test [see Dosage and Administration (2.1)], whose disease has progressed on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). 2 DOSAGE AND ADMINISTRATION 2.1 Patient Selection Select patients with locally advanced or metastatic NSCLC for treatment with EXKIVITY based on the presence of EGFR exon 20 insertion mutations 
Additional Information